Page 2 - Gautam Jayram News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Theralase Technologies Inc.: Theralase Launches Second Clinical Study Site in the US for Phase II Bladder Cancer Clinical Study
TSXV:TLT)(
OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (
PDC ) and their associated drug formulations used to safely and effectively destroy various cancers, bacteria and viruses announced today that Urology Associates P.C. (
UA ) has received site Institutional Review Board (
IRB ) approval to commence a pivotal phase II Non-Muscle Invasive Bladder Cancer (
NMIBC ) Clinical Study to enroll and treat patients with Bacillus Calmette Guerin(

Study II ).
Theralase has central IRB approval to launch a number of US clinical sites, subject to local site IRB approval. UA is the second site to receive both central and local site IRB approval. There are 4 additional US clinical study sites that have received central IRB approval an ....

United States , Gautam Jayram , Kristina Hachey , Calmette Guerin , Urology Associates , Therapeutic Center , Theralase Or Company , Technologies Inc , Women Institute For Sexual Health , Urology Surgery Center , Therapeutics Center , Venture Exchange , Regulation Services Provider , Theralase Technologies Inc , Photo Dynamic Compounds , Institutional Review Board , Muscle Invasive Bladder Cancer , Clinical Study , Bacillus Calmette Guerin , Unresponsive Carcinoma In Situ , Middle Tennessee , Practice Providers , Sexual Health , Advanced Therapeutics , Urologic Oncologist , Advanced Therapeutic Center ,